# Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

> **NCT04892017** · PHASE1 · TERMINATED · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 91 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** Inlexisertib
- **DRUG:** Trametinib
- **DRUG:** Binimetinib
- **DRUG:** Sotorasib

## Key facts

- **NCT ID:** NCT04892017
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-15
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** Trial terminated due to business decision, not based on any safety or efficacy concerns.
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892017, "Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT04892017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*